Chiappinelli Katherine B, Strissel Pamela L, Desrichard Alexis, Li Huili, Henke Christine, Akman Benjamin, Hein Alexander, Rote Neal S, Cope Leslie M, Snyder Alexandra, Makarov Vladimir, Budhu Sadna, Slamon Dennis J, Wolchok Jedd D, Pardoll Drew M, Beckmann Matthias W, Zahnow Cynthia A, Merghoub Taha, Chan Timothy A, Baylin Stephen B, Strick Reiner
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA.
Department of Gynaecology and Obstetrics, Laboratory for Molecular Medicine, University-Clinic Erlangen, 91054 Erlangen, Germany.
Cell. 2015 Aug 27;162(5):974-86. doi: 10.1016/j.cell.2015.07.011.
We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway. In ovarian cancer (OC), DNMTis trigger cytosolic sensing of double-stranded RNA (dsRNA) causing a type I interferon response and apoptosis. Knocking down dsRNA sensors TLR3 and MAVS reduces this response 2-fold and blocking interferon beta or its receptor abrogates it. Upregulation of hypermethylated endogenous retrovirus (ERV) genes accompanies the response and ERV overexpression activates the response. Basal levels of ERV and viral defense gene expression significantly correlate in primary OC and the latter signature separates primary samples for multiple tumor types from The Cancer Genome Atlas into low versus high expression groups. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.
我们发现,DNA甲基转移酶抑制剂(DNMTis)通过病毒防御途径上调癌症中的免疫信号。在卵巢癌(OC)中,DNMTis触发双链RNA(dsRNA)的胞质感应,引发I型干扰素反应和细胞凋亡。敲低dsRNA传感器TLR3和MAVS可使这种反应降低两倍,而阻断干扰素β或其受体则可消除这种反应。高甲基化内源性逆转录病毒(ERV)基因的上调伴随着这种反应,并且ERV的过表达会激活这种反应。原发性OC中ERV和病毒防御基因表达的基础水平显著相关,并且后者的特征将来自癌症基因组图谱的多种肿瘤类型的原发性样本分为低表达组和高表达组。在接受免疫检查点治疗的黑色素瘤患者中,肿瘤中高病毒防御特征表达与持久的临床反应显著相关,并且在临床前黑色素瘤模型中,DNMTi治疗可使对抗CTLA4治疗敏感。